Cambridge spin-out XO1, which is developing anticoagulants that could have a sizeable impact on preventing heart attacks and strokes, has received $11m from Index Ventures.

The life science investor was the sole participant in the $11m round, made through Index’s $200m Life Sciences fund launched last year, and represents the company’s largest investment in a life science company to date.

The funding will be used to develop ichorcumab, an antibody created by researchers at the University of Cambridge and affiliated…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?